
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech Inc has demonstrated strong revenue growth, with a notable 28% year-over-year increase in its soft tissue repair products, particularly driven by higher demand for its CellerateRX Surgical Activated Collagen. Furthermore, the company has achieved a 25% year-over-year growth in its bone fusion products, indicating a robust performance across its product segments. With a strategic focus on expanding distribution partnerships and increasing penetration in healthcare facilities, the company is well-positioned to sustain topline growth in the coming year.
Bears say
Sanara MedTech faces significant risks that may adversely affect its financial performance, including lower-than-projected revenue growth and challenges in securing additional customers. The company also encounters obstacles regarding the successful launch of new products or services, which could hinder its market competitiveness. Additionally, potential dilution risk poses a further threat to shareholder value and overall investment viability.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares